Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis

Cyriel Y. Ponsioen, Keith D. Lindor, Ruby Mehta, Lara Dimick-Santos

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Primary sclerosing cholangitis (PSC) is a rare and chronic liver disease for which there is no effective therapy. Interest has grown in developing treatments for this condition, with several agents proposed as potential therapies. However, there is a lack of clarity about how to measure clinical benefit in trials involving patients with this complex and rare disease. This article reviews regulatory information, the available literature on natural history, as well as potential candidate clinical and surrogate endpoints for PSC. (Hepatology 2018; 00:000-000).
Original languageEnglish
Pages (from-to)1174-1188
JournalHepatology (Baltimore, Md.)
Volume68
Issue number3
DOIs
Publication statusPublished - 2018

Cite this